Cargando…

Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection

At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: “This is a long story, that shouldn’t be long, but it will take a long time to make it short”. As it happens, such a statement would apply...

Descripción completa

Detalles Bibliográficos
Autor principal: Carafoli, Ernesto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524676/
https://www.ncbi.nlm.nih.gov/pubmed/33028485
http://dx.doi.org/10.1016/j.bbrc.2020.09.128
_version_ 1783588590268186624
author Carafoli, Ernesto
author_facet Carafoli, Ernesto
author_sort Carafoli, Ernesto
collection PubMed
description At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: “This is a long story, that shouldn’t be long, but it will take a long time to make it short”. As it happens, such a statement would apply perfectly well to the story of chloroquine (CQ) and hydroxychloroquine (HCQ) in the COVID-19 infection: it has become a veritable saga, with conflicting views that have often gone beyond the normal scientific dialectic, and with conclusions that have frequently been polluted by non scientific opinions: thus, for instance, when National Agencies have taken positions against CQ and HCQ, the move has been seen as a pro-vaccine attempt to block low cost therapy means. And it is difficult to avoid the feeling that the opposition to CQ and HCQ has in large measure been shaped not by scientific arguments, but by the fact that their use has been strongly endorsed by National leaders whose popularity among Western intellectuals is extremely low. The role of the two drugs in the COVID-19 infection thus deserves an objective analysis solely based on scientific facts. This contribution will attempt to produce it.
format Online
Article
Text
id pubmed-7524676
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-75246762020-09-30 Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection Carafoli, Ernesto Biochem Biophys Res Commun Article At the end of last century a prominent biochemist once opened the discussion of a controversial issue in the field of Bioenergetics with the following statement: “This is a long story, that shouldn’t be long, but it will take a long time to make it short”. As it happens, such a statement would apply perfectly well to the story of chloroquine (CQ) and hydroxychloroquine (HCQ) in the COVID-19 infection: it has become a veritable saga, with conflicting views that have often gone beyond the normal scientific dialectic, and with conclusions that have frequently been polluted by non scientific opinions: thus, for instance, when National Agencies have taken positions against CQ and HCQ, the move has been seen as a pro-vaccine attempt to block low cost therapy means. And it is difficult to avoid the feeling that the opposition to CQ and HCQ has in large measure been shaped not by scientific arguments, but by the fact that their use has been strongly endorsed by National leaders whose popularity among Western intellectuals is extremely low. The role of the two drugs in the COVID-19 infection thus deserves an objective analysis solely based on scientific facts. This contribution will attempt to produce it. Published by Elsevier Inc. 2021-01-29 2020-09-30 /pmc/articles/PMC7524676/ /pubmed/33028485 http://dx.doi.org/10.1016/j.bbrc.2020.09.128 Text en © 2020 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Carafoli, Ernesto
Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
title Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
title_full Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
title_fullStr Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
title_full_unstemmed Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
title_short Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection
title_sort chloroquine and hydroxychloroquine in the prophylaxis and therapy of covid-19 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524676/
https://www.ncbi.nlm.nih.gov/pubmed/33028485
http://dx.doi.org/10.1016/j.bbrc.2020.09.128
work_keys_str_mv AT carafoliernesto chloroquineandhydroxychloroquineintheprophylaxisandtherapyofcovid19infection